TY  - GEN 
AU  - Stuckey, R.
AU  - Segura-Dí­az, A.
AU  - Sáez Perdomo, M.N.
AU  - Pérez Encinas, Manuel Mateo
AU  - González San Miguel, J.D.
AU  - Florido, Y.
AU  - Sánchez-Sosa, S.
AU  - López-Rodrí­guez, J.F.
AU  - Bilbao-Sieyro, C.
AU  - Gómez-Casares, M.T.
PY  - 2023
SN  - 2072-6694
UR  - http://hdl.handle.net/20.500.11940/20302
AB  - For chronic myeloid leukemia (CML) patients with a known risk of cardiovascular events (CVE), imatinib is often recommended for first-line tyrosine kinase inhibitor (TKI) treatment rather than a second-generation TKI (2G-TKI) such as nilotinib or...
LA  - eng
TI  - Presence of Myeloid Mutations in Patients with Chronic Myeloid Leukemia Increases Risk of Cardiovascular Event on Tyrosine Kinase Inhibitor Treatment
DO  - 10.3390/CANCERS15133384
KW  - AS Santiago AP
KW  - CHUS
VL  - 15
ER  -